Amplexa Genetics

What Amplexa Genetics does

Amplexa Genetics A/S is a privately held, ISO 15189-certified genetic testing laboratory founded in 2006 and headquartered in Odense, Denmark. It operates as a clinical services provider delivering diagnostic genetic tests to healthcare professionals — primarily fertility clinics, clinical geneticists, neurologists, and epilepsy specialists — across neurology, endocrinology, cardiology, and oncology-related applications, with a stated reach into at least five European-language markets (English, Danish, Spanish, Faroese, Russian).

The company's product portfolio is organized into three clinical franchises (Fertility, Clinical, Neurology) plus a Technical Services and R&D line. Core offerings include non-invasive preimplantation genetic testing for aneuploidies (niPGT-A), carrier screening panels (Genes4Life at 428 genes; X-Linked Carrier Test), donor screening programs (sperm and egg), the EPIDASD epilepsy/intellectual disability/autism panel (1,740 genes), Trio Exome Analysis, and condition-specific panels for Ehlers-Danlos, endocrinology, ophthalmology, rickets, thrombophilia, and familial hemiplegic migraine. Underlying technology relies on Next Generation Sequencing on Illumina NovaSeq 6000 with Twist Biosystems Human Core Exome chemistry, supplemented by TP-PCR for repeat-expansion disorders (e.g., FMR1/Fragile X) and MLPA for copy-number variants, all processed through an in-house bioinformatics pipeline integrating machine learning algorithms with public annotation databases and prediction tools (SIFT, PolyPhen, MutationTaster, AION, SpliceFinder). A separate R&D line offers bulk RNA sequencing, single-cell RNA sequencing, and end-to-end bioinformatics services.

Amplexa's commercial model is B2B sales-led: clinicians place orders via standardized online forms (Formstack), receive sample collection kits, and obtain reports directly from the laboratory. Revenue is generated through one-time test fees and project-based research services, with no public pricing. The firm pursues grant-funded research collaborations with the University of Southern Denmark, University of Copenhagen, King's College London, and several Danish and UK clinical partners, supplemented by funding from Innovation Fund Denmark, Epilepsy Research UK, Danish Life Science Cluster, and Eurostars. Ownership is private, with no disclosed parent company or institutional investors, and headcount is reported as 1–10 employees.

Name

Amplexa Genetics

Legal name

Amplexa Genetics A/S

Website

https://amplexa.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

1–10 employees

Short description

Amplexa Genetics is an ISO 15189-certified Danish genetic testing laboratory, founded 2006, providing clinical and fertility genetic panels (including non-invasive PGT-A and a 1,740-gene epilepsy panel) to clinicians, fertility clinics, and neurologists across European markets.

Ownership category

akta.pro rank

Product category

Clinical Genetic Testing Services

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Genetic & Prenatal Testing Laboratories (HLAFAMAH)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ), Neurogenetics & Rare Neurologic Diseases (HLAKAIAO)

Keywords

• Clinical genetic testing
• Fertility genetic screening
• Next generation sequencing
• Carrier screening panels
• Neurological genetic diagnostics

Headquarters

HQ city

Odense

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Genetic Testing Services: Laboratory testing services providing genetic analysis for clinical diagnosis. Includes specialized panels for neurology, clinical conditions, and fertility applications. Turnaround time typically 3-5 weeks.
2. Fertility Genetic Testing: Preimplantation genetic testing (niPGT-A), carrier screening programs (Genes4Life, Genes4Life Plus, X-Linked Carrier Test), and donor screening for sperm and egg donors.
3. Technical and Research Services: NGS solutions, MLPA, TP-PCR, bulk RNA sequencing, single-cell sequencing, and bioinformatics services for research and commercial collaborators.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Amplexa Genetics is a Danish ISO 15189-certified clinical laboratory founded in 2006 that provides genetic diagnostic and screening services to healthcare professionals. Its core offerings span fertility genetics (non-invasive PGT-A, carrier screening such as Genes4Life, donor screening), clinical neurology panels (Epidasd epilepsy/intellectual disability/autism, FMR1 fragile X, focal cortical dysplasia), broader clinical panels (Ehlers-Danlos, endocrinology, ophthalmology, rickets, thrombophilia), and technical/research services including NGS, MLPA, TP-PCR, single-cell sequencing, and bioinformatics.

Product overview

Amplexa Genetics offers a comprehensive genetic testing portfolio organized into three main categories: Fertility Solutions (non-invasive PGT-A, carrier screening including Genes4Life and X-Linked Carrier Test, donor screening programs), Clinical and Neurology Panels (Trio Exome Analysis, Epidasd for epilepsy/intellectual disability/autism, and specialty panels for Ehlers-Danlos, endocrinology, ophthalmology, rickets, thrombophilia, and familial hemiplegic migraine), and Technical/Research Services (NGS solutions, MLPA, TP-PCR, bulk and single-cell RNA sequencing, and bioinformatics). The company operates as a laboratory services provider offering both diagnostic panels and research-grade sequencing solutions, with products ranging from targeted single-gene tests to whole exome and genome sequencing.

Differentiator

Problem solved

Functional benefit

Products and services

• Non-Invasive PGT-A (niPGT-A) Non-invasive preimplantation genetic test for aneuploidies that analyzes cell-free DNA from spent IVF culture medium to identify chromosomal abnormalities in embryos, increasing IVF success rates for fertility clinics.
• Genes4Life Carrier screening panel analyzing 428 genes for recessive genetic diseases to help identify genetically compatible egg or sperm donors and inform fertility treatment decisions.
• Genes4Life Plus Extended carrier screening panel that analyzes additional recessive disease genes beyond the standard Genes4Life panel for more comprehensive fertility genetic assessment.
• X-Linked Carrier Test Genetic screening panel analyzing 12 X-linked genes to identify female carriers of recessive X-linked diseases prior to pregnancy planning.
• Sperm Donor Screening Whole exome screening program for sperm donors to ensure genetic safety and compatibility for individuals and families using donor sperm.
• Egg Donor Screening Whole exome screening program for egg donors to ensure genetic compatibility and safety for fertility treatment recipients.
• Match4Life Donor matching program that helps fertility patients find genetically compatible sperm or egg donors based on carrier screening results.
• Epidasd Comprehensive 1740-gene panel for epilepsy, intellectual disability, and autism spectrum disorders, providing diagnostic genetic testing for neurology specialists.
• EpidasdACT° Extended epilepsy and developmental disorder panel offering additional clinical interpretation features beyond the core 1740-gene Epidasd panel.
• Familial Hemiplegic Migraine Panel Genetic screening panel for 4 genes (ATP1A2, CACNA1A, SCN1A) associated with familial hemiplegic migraine to support precision medicine diagnosis.
• Focal Cortical Dysplasia Panel Genetic panel for focal cortical dysplasia and related brain malformation disorders, supporting neurology and epilepsy specialists.
• Brain Malformation Panel Genetic testing panel for brain malformations and developmental brain disorders for neurology specialists.
• Fragile X Syndrome Test (FMR1) TP-PCR-based FMR1 CGG repeat expansion test for fragile X syndrome, delivering 100% diagnostic sensitivity and 98.4% specificity for clinical diagnosis.
• Trio Exome Analysis Family pedigree analysis using whole exome sequencing on patient, parent, and grandparent samples to identify inherited disease-causing mutations and de novo variants.
• Ehlers-Danlos Syndromes Panel Clinical genetic panel for diagnosis and classification of Ehlers-Danlos syndromes for clinicians and clinical geneticists.
• Endocrinology Panel Clinical genetic panel for hereditary endocrine disorders.
• Late-Onset Dominant Disorders Panel Clinical genetic panel for late-onset autosomal dominant genetic disorders.
• Ophthalmology Panel Clinical genetic panel for hereditary ophthalmological conditions.
• Rickets Panel Clinical genetic panel for hereditary rickets and skeletal disorders.
• Thrombophilia Panel Clinical genetic panel for thrombophilia and hereditary blood clotting disorders.
• SRY Genetic Testing SRY gene test for gender determination in sports and clinical applications.
• NGS Solutions Next Generation Sequencing services including whole genome, whole exome, targeted panel, and RNA sequencing for research and commercial collaborators.
• MLPA Multiplex Ligation-dependent Probe Amplification service for detection of gene deletions and duplications.
• TP-PCR Triplet Repeat Primed PCR service for repeat expansion disorder testing including fragile X syndrome.
• Bulk RNA Sequencing Bulk RNA sequencing service for gene expression analysis in research samples.
• Single Cell Sequencing Single-cell RNA sequencing (scRNAseq) service for cell-type-specific transcriptional analysis.
• Bioinformatics Service End-to-end bioinformatics support covering experimental design, sequencing data analysis, interpretation, and publication-ready figure generation.

Quantifiable outcome

• Diagnostic yield of 34% in patients with seizure onset <2 years, compared to 4% for onset >2 years
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core, major and minor.

• University of Southern Denmark (Prof. Ditte C. Andersen)coreStrategic or Co-development PartnerResearch collaboration on single-cell sequencing applications. Industrial PhD project on transcriptomic analysis for induced pluripotent stem cell systems. Financed by Innovation Fund Denmark.
• University of Copenhagen (Prof. Hanne Ingmer)coreStrategic or Co-development PartnerResearch collaboration on single-cell RNA sequencing platform for bacteria to delineate antibiotic hetero-resistance. Also collaboration partner on sBACseqFOOD project with Matís Iceland.
• IVF-Syd (Steen Broch Laursen)coreStrategic or Co-development PartnerCollaboration on enhancing fertility treatment through advanced non-invasive preimplantation genetic testing for aneuploidy (niPGT-A) project.
• Herlev and Gentofte Hospital (Marie Louise Grøndahl)coreStrategic or Co-development PartnerAcademic collaboration on niPGT-A research project for fertility treatment enhancement.
• King's College London (Prof. Joseph Bateman, Prof. Deb Pal)majorStrategic or Co-development PartnerResearch collaboration on understanding focal cortical dysplasia: A path to novel treatments. Also includes Dr Frances Elmslie from St George's Hospital and Dr Laura Mantoan and Dr Charlotte Tye from King's College.
• Matís IcelandminorStrategic or Co-development PartnerPartner in sBACseqFOOD project focused on food safety. Eurostars funded project.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Invitae: Large clinical genetics laboratory offering comprehensive hereditary disease, reproductive, and oncology panels. Competes across multiple of Amplexa's product categories with substantially more resources and global reach.
• Natera: Large-scale reproductive and oncology genetics company offering PGT-A, carrier screening, and clinical panels. Competes with Amplexa's fertility products but operates at substantially larger scale and broader geographic reach.
• GeneDx: Clinical genomics company offering whole exome sequencing and specialty panels for rare disease and neurodevelopmental disorders. Overlaps with Amplexa's neurology/clinical genetics franchise at significantly greater scale.

Direct peers

• Blueprint Genetics: Clinical genetics laboratory offering specialty panels for hereditary conditions, neurology, and rare disease diagnostics. Comparable mid-size specialty lab competing for similar clinical customer segments in neurology and clinical genetics.
• Medicover Genetics: European genetic testing services provider operating across multiple countries with NIPT, PGT, and clinical panels. Comparable European footprint and reproductive/clinical genetics mix.
• Centogene: Rostock-based rare disease and neurogenetics diagnostic laboratory offering similar genetic testing panels for neurology, metabolic disorders, and reproductive indications. Closest direct peer given its European specialty lab profile and clinical focus.
• Igenomix: Reproductive genetics laboratory specializing in PGT, carrier screening, and IVF-focused genetic testing. Directly comparable to Amplexa's fertility franchise including PGT-A and donor screening.
• Prevention Genetics: US-based clinical genetic testing laboratory offering whole exome sequencing, targeted panels, and carrier screening. Similar mid-sized specialty lab profile with comparable NGS service offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amplexa-genetics-a-s

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amplexa Genetics